Inventor
GILMORE JOHN L
US28 patents
⚠️ This page may combine multiple inventors who share the name “GILMORE JOHN L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
24 patentsUS7211671B2May 1, 2007
Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
BRISTOL MYERS SQUIBB CO15 citations83
US11053244B1Jul 6, 2021
4-azaindole compounds
BRISTOL MYERS SQUIBB CO6 citations82
US10730877B2Aug 4, 2020
4-Azaindole compounds
BRISTOL MYERS SQUIBB CO6 citations82
US10166249B2Jan 1, 2019
Substituted bicyclic compounds
BRISTOL MYERS SQUIBB CO2 citations73
US7253283B2Aug 7, 2007
Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
BRISTOL MYERS SQUIBB CO6 citations73
US11447466B2Sep 20, 2022
Substituted indole compounds useful as inhibitors of TLR7/8/9
BRISTOL MYERS SQUIBB CO3 citations72
US11701373B2Jul 18, 2023
Substituted bicyclic compounds
BRISTOL MYERS SQUIBB CO0 citations62
US11058696B2Jul 13, 2021
Substituted bicyclic compounds
BRISTOL MYERS SQUIBB CO0 citations62
US11046646B2Jun 29, 2021
Alkylphenyl compounds
BRISTOL MYERS SQUIBB CO0 citations62
US9522888B2Dec 20, 2016
Substituted bicyclic compounds
BRISTOL MYERS SQUIBB CO2 citations62
US11820768B2Nov 21, 2023
4-azaindole compounds
BRISTOL MYERS SQUIBB CO0 citations61
US7074810B2Jul 11, 2006
Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
BRISTOL MYERS SQUIBB CO6 citations60
US11597721B2Mar 7, 2023
Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses
BRISTOL MYERS SQUIBB CO1 citations59
US12172995B2Dec 24, 2024
Substituted indole and indazole compounds
BRISTOL MYERS SQUIBB CO0 citations52
US10709719B2Jul 14, 2020
Substituted bicyclic compounds
BRISTOL MYERS SQUIBB CO0 citations52
US9770459B2Sep 26, 2017
Substituted bicyclic compounds
BRISTOL MYERS SQUIBB CO0 citations52
US12240840B2Mar 4, 2025
Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
BRISTOL MYERS SQUIBB CO0 citations51
US11998537B2Jun 4, 2024
Substituted indole dimer compounds
BRISTOL MYERS SQUIBB CO0 citations51
US11739098B2Aug 29, 2023
Substituted indole compounds
BRISTOL MYERS SQUIBB CO0 citations51
US7544808B2Jun 9, 2009
Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
BRISTOL MYERS SQUIBB CO0 citations51
US11878975B2Jan 23, 2024
Substituted indole compounds useful as TLR inhibitors
BRISTOL MYERS SQUIBB CO0 citations50
US7625921B2Dec 1, 2009
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
BRISTOL MYERS SQUIBB CO0 citations41
US7569689B2Aug 4, 2009
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
BRISTOL MYERS SQUIBB CO0 citations41
US7605264B2Oct 20, 2009
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
BRISTOL MYERS SQUIBB CO0 citations40